Topical Treatment for EB Recommended for Approval in the EU

In February, the FDA declined to approve the company's new drug application as it was presented and asked the company to submit additional evidence of effectiveness for epidermolysis bullosa (EB).
International Approvals

source https://www.medscape.com/viewarticle/972788?src=rss